Acrux Ltd (ASX: ACR) Share Price and News

Price

$0.023

Movement

0.00 (0.0)

as at 7 May - Closed (20 mins delayed)

52 Week Range

$0.022 - $0.088

 
1 Year Return

-62.9%

Acrux Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $9.37 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 407.32 million
Earnings per share -0.020
Dividend per share N/A
Year To Date Return -30.30%
Earnings Yield N/A
Franking -
Share Price

$0.023

Day Change

0.00 (0.0)

52 Week Range

$0.022 - $0.088

Yesterday's Close

$0.023

Today's Open

$0.023

Days Range

$0.023 - $0.023

Volume

145,200

Avg. Volume (1 month)

123,038

Turnover

$3,340

as at 7 May - Closed

  • Acrux Ltd (ASX: ACR)
    Latest News

    a woman
    Investing

    3 solid stocks that Mr Market hates today

    1 tech company, 1 mining services company and 1 pharmaceutical company: you need to know these 3 potential bargains...

    Read more »

    a woman
    Investing

    5 health care stocks to supercharge your portfolio

    The health sector is a growth investor’s dream.

    Read more »

    a woman
    Investing

    2 pharmaceutical stocks growing sales in the giant US drug market – should you buy?

    More products in the development pipeline will be driving earnings.

    Read more »

    a woman
    Investing

    Could these 4 bruised biotech stocks be about to recover?

    Investing in the biotech sector can be hit or miss, but the hits can well and truly make up for…

    Read more »

    a woman
    Investing

    Your instant 6-share biotech portfolio

    For investors prepared to add some risk to their portfolio, the biotech industry can offer plenty of choice.

    Read more »

    a woman
    Investing

    Acrux Limited tumbles 10.3%

    Mystery surrounds the drop in the drug developer’s share price.

    Read more »

    ACR ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Acrux Ltd

    Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and othercountries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone TopicalSolution, and among others.

    ACR Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    06 May 2025 $0.02 $0.00 0.00% 62,393 $0.02 $0.02 $0.02
    05 May 2025 $0.02 $0.00 0.00% 20,119 $0.02 $0.02 $0.02
    02 May 2025 $0.02 $0.00 0.00% 60,000 $0.02 $0.02 $0.02
    01 May 2025 $0.02 $0.00 0.00% 171,564 $0.02 $0.02 $0.02
    29 Apr 2025 $0.02 $0.00 0.00% 11,636 $0.02 $0.02 $0.02
    28 Apr 2025 $0.02 $0.00 0.00% 84,748 $0.02 $0.02 $0.02
    24 Apr 2025 $0.02 $0.00 0.00% 43,716 $0.02 $0.02 $0.02
    23 Apr 2025 $0.02 $0.00 0.00% 10,659 $0.02 $0.02 $0.02
    22 Apr 2025 $0.02 $0.00 0.00% 179,089 $0.02 $0.02 $0.02
    17 Apr 2025 $0.02 $0.00 0.00% 67,726 $0.02 $0.02 $0.02
    16 Apr 2025 $0.02 $0.00 0.00% 447,430 $0.02 $0.02 $0.02
    15 Apr 2025 $0.02 $0.00 0.00% 113,820 $0.02 $0.02 $0.02
    14 Apr 2025 $0.02 $0.00 0.00% 77,445 $0.02 $0.02 $0.02
    11 Apr 2025 $0.02 $0.00 0.00% 82,528 $0.02 $0.02 $0.02
    10 Apr 2025 $0.02 $0.00 0.00% 614,298 $0.02 $0.02 $0.02
    09 Apr 2025 $0.03 $0.00 0.00% 9,252 $0.03 $0.03 $0.03

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    04 Apr 2025 Ross Dobinson Issued 571,428 $12,571
    Placement. As per announcement on 04-04-2025
    04 Mar 2025 Ross Dobinson Issued 571,428 $20,000
    Placement.
    19 Feb 2025 Geoffrey Brooke Issued 285,714 $8,857
    Placement.
    19 Feb 2025 Timothy Oldham Issued 285,714 $8,857
    Placement.
    19 Feb 2025 Michael Kotsanis Issued 857,142 $26,571
    Placement. As per announcement on 19-02-2025
    19 Feb 2025 Donald Brumley Issued 2,285,714 $70,857
    Placement.
    13 Feb 2025 Donald Brumley Issued 2,285,714 $80,000
    Placement.
    13 Feb 2025 Michael Kotsanis Issued 857,142 $30,000
    Placement.
    13 Feb 2025 Geoffrey Brooke Issued 285,714 $10,000
    Placement.
    13 Feb 2025 Timothy Oldham Issued 285,714 $10,000
    Placement.
    12 Dec 2024 Donald Brumley Issued 797,210 $25,510
    Conversion of securities.
    12 Dec 2024 Donald Brumley Issued 896,668 $28,693
    Issue of securities. 1,693,878 Rights
    12 Dec 2024 Donald Brumley Exercise 797,210 $25,510
    Conversion of securities.
    12 Dec 2024 Timothy Oldham Exercise 1,062,946 $34,014
    Conversion of securities. 896,668 unlisted rights
    12 Dec 2024 Timothy Oldham Issued 1,062,946 $34,014
    Conversion of securities.
    12 Dec 2024 Timothy Oldham Issued 896,668 $28,693
    Issue of securities. 1,959,614 Rights
    12 Dec 2024 Ross Dobinson Issued 1,411,994 $45,183
    Issue of securities. 2,668,548 Rights
    12 Dec 2024 Geoffrey Brooke Issued 896,668 $28,693
    Issue of securities. 1,959,614 rights

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Ross Dobinson Non-Executive ChairmanNon-Executive Director Jul 2012
    Mr Dobinson has a background in investment banking and stockbroking. He was a founding Director of Starpharma Holdings Limited (ASX: SPL) and was formerly a Director of Reliance Worldwide Corporation (ASX: RWC), Executive Director of Hexima Limited (ASX: HXL), Chairman of TPI Enterprises Limited (now Palla Pharma Ltd. ASX: PAL), Director of Roc Oil Company Limited (ASX: ROC) and a Director of Racing Victoria Limited.
    Dr Geoffrey E.D Brooke Non-Executive Director Jun 2016
    Dr Brooke has more than 30 years of venture capital experience. In 2014, he sold his involvement in GBS and now concentrates on privately investing in a small number of companies. He is a member of Risk and Human Capital Committee.
    Dr Timothy Oldham Non-Executive Director Oct 2013
    Dr Oldham has 20 years of life sciences business development, alliance management and sales and marketing experience in Europe, Asia and Australia. He is the Chair of the Human Capital Committee and also a member of Risk Committee.
    Mr Michael John Kotsanis Chief Executive OfficerManaging Director Nov 2014
    Mr Kotsanis has more than 30 years of experience in the global pharmaceutical industry including significant senior leadership experience. Prior to Faulding, Michael held a variety of sales and marketing positions with a German multinational pharmaceutical company over an 11-year period.
    Mr Donald Charles Brumley Non-Executive Director Jun 2021
    Mr Brumley has 30 years of experience as a senior partner of Ernst & Young, Oceania. He has experience in IPOs, transactions and audit and has advised and worked with Boards of organisations ranging from some of the largest in Australia to fast growing entrepreneurial and medium sized organisations. He is the Chair of the Risk Committee and also a member of Human Capital Committee.
    Ms Joanna Johnson Chief Financial OfficerCompany Secretary Jun 2021
    -
    Joanna Johnson Chief Financial OfficerCompany Secretary
    -
    Felicia Colagrande Product Development and Technical Affairs Director
    -
    Mark Hyman Project and Technical Development Director
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Phillip Asset Management Limited 31,847,134 10.95%
    Hishenk Pty Ltd 11,000,000 3.78%
    Mr Ross Dobinson 5,249,245 1.81%
    Dr Thomas Vui Chung Chai 4,951,985 1.70%
    Willoughby Capital Pty Ltd 4,500,000 1.55%
    Citicorp Nominees Pty Limited 4,149,492 1.43%
    Mr Christopher Murray Abbott 4,000,000 1.38%
    Ashwood River Pty Ltd 3,800,000 1.31%
    The Poole Family Superannuation Fund Pty Ltd 3,700,000 1.27%
    Mr Donald Charles Brumley 3,396,108 1.17%
    Netwealth Investments Limited 3,284,269 1.13%
    Mr Alan Jebb & Mrs Sandra Jebb 3,100,000 1.07%
    MNA Family Holdings Pty Ltd 2,800,000 0.96%
    TSO Pty Ltd 2,625,734 0.90%
    Mr Bikash Kaji Baniya 2,339,711 0.80%
    HSBC Custody Nominees (Australia) Limited 2,100,674 0.72%
    Pacific Custodians Pty Limited 2,048,427 0.70%
    Mr Ian Victor Lancini & Mrs Debra Ann Lancini 2,045,000 0.70%
    Mr Zirong Pu 2,023,000 0.70%
    Adam Jamal 1,905,719 0.66%
    Mr Michael John Kotsanis 1,511,083 0.52%
    Mr Allen James Kirby 1,500,000 0.52%
    Mr David Andrew Slobom & Mrs Linda Jane Slobom 1,409,596 0.48%
    NewEconomy Com Au Nominees Pty Limited 1,327,870 0.46%
    Mrs Nola Kendall Fletcher 1,300,000 0.45%

    Profile

    since

    Note